Popular immunotherapy target turns out to have a surprising buddy
(WorldNews Netherlands)

The majority of current cancer immunotherapies focus on PD-L1. This well studied protein turns out to be controlled by a partner, CMTM6, a previously unexplored molecule that is now suddenly also a potential therapeutic target. Researchers from the Netherlands Cancer Institute publish these findings in the leading journal Nature on August 16. Immunotherapy is an exciting new way of treating cancer. The immune cells that circulate throughout the human body are supposed to attack and eliminate any cancer cells they encounter. However, some cancers have found a...